Komori
Business Alliance4591RIBOMIC Inc.Pharmaceuticals

Notice of Execution of a Technology Evaluation Agreement Regarding DDS Aptamer Technology

The company has entered into an agreement to provide its DDS aptamer technology to an overseas biotechnology company, which will conduct a technology evaluation. The company expects to receive US$53,000 in consideration, but the agreement does not guarantee a business partnership or joint research.

Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
53000
US dollars
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Details of the alliance
  1. 1

    The counterparty will evaluate the DDS (Drug Delivery System) aptamer technology owned by the company.

  2. 2

    Provision of the company's DDS aptamer technology

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionOverseas biotechnology company
LocationOverseas (country and location: Not disclosed)
Impact on Business Performance

The consideration that the company expects to receive under this agreement is expected to be recognised as business revenue for the fiscal year ending March 2027.

Agreements reached under this partnership
ItemDetails
Alliance partner's business activitiesOverseas biotechnology company
Alliance partner's locationOverseas (country and location: Not disclosed)
Details of the allianceThe counterparty will evaluate the DDS (Drug Delivery System) aptamer technology owned by the company., Provision of the company's DDS aptamer technology
Impact on Business PerformanceThe consideration that the company expects to receive under this agreement is expected to be recognised as business revenue for the fiscal year ending March 2027.
Items this document does not state (19)
Name of alliance partnerAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To enable the counterparty to evaluate the company's DDS aptamer technology, and to promote future research and development and create new business opportunities.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Execution of a Technology Evaluation Agreement Regarding DDS Aptamer Technology | RIBOMIC Inc. (4591) timely disclosure | Komori